'Placebo dalcetrapib' presentation slideshows

HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo

HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo. 70. 60. placebo. 30. dalcetrapib. 50. HDL-cholesterol (mg/dL). 20. % change from baseline in non-ABCA1-specific cholesterol efflux. 40. placebo. dalcetrapib. 30. 10. 20. 0. 0. 4. 8.

137 views • 1 slides